Management of Asymptomatic CAD with Prior GI Bleeding

Medical Management Strategy

The American College of Cardiology recommends single antiplatelet therapy with aspirin 75-100 mg daily for stable CAD without recent stenting, in patients with a history of GI bleeding 1
If aspirin is contraindicated due to recurrent GI bleeding despite PPI use, the European Society of Cardiology suggests clopidogrel 75 mg daily as a safe and effective alternative 1, 2
The European Heart Association advises avoiding ticagrelor or prasugrel in stable CAD patients with high bleeding risk, as these agents increase bleeding risk compared to clopidogrel 3, 4, 2

PPI co-prescription is mandatory in patients with a GI bleed history, according to the European Heart Association, to reduce recurrent bleeding risk 4, 5, 6
The American College of Gastroenterology recommends continuing PPIs indefinitely while on any antiplatelet therapy to reduce recurrent bleeding risk 1

For patients at high bleeding risk, the European Heart Association recommends shortening DAPT duration to 3 months after drug-eluting stent placement 4, 6, 2
The European Society of Cardiology suggests standard DAPT duration is 6 months for elective PCI with drug-eluting stents, but this should be reduced to 1-3 months when bleeding safety concerns exist 3, 4
After completing shortened DAPT, the American College of Cardiology recommends transitioning to aspirin monotherapy with PPI 1

The European Heart Association prefers clopidogrel over ticagrelor or prasugrel in patients with prior GI bleeding 3, 4, 5

The European Society of Cardiology advises not discontinuing both antiplatelet agents simultaneously, as complete DAPT interruption is an independent predictor of stent thrombosis and mortality 3, 4, 5
The American College of Gastroenterology recommends maintaining at least aspirin therapy during acute bleeding if hemodynamically tolerable 1
Urgent interventional endoscopy should be performed to identify and treat the bleeding source, allowing earlier resumption of antiplatelet therapy, according to the European Heart Association 3, 4
The European Heart Association advises avoiding red blood cell transfusion unless hemodynamically compromised, as transfusion has been shown to be detrimental in patients with known CAD 3, 4, 5

Postpone any elective coronary interventions until bleeding has resolved and the patient can safely tolerate antiplatelet therapy, recommends the European Society of Cardiology 3, 4, 6

The American College of Cardiology recommends continuing aspirin if possible rather than interrupting it for elective endoscopy or surgery 1
If aspirin must be discontinued due to high bleeding risk, the American College of Cardiology suggests limiting interruption to 5 days maximum 1
Non-urgent surgery should be delayed for at least 12 months after coronary stent placement, according to the American College of Cardiology 1

The European Heart Association advises never using ticagrelor or prasugrel in stable CAD patients with GI bleeding history, as this inappropriately escalates bleeding risk without evidence of benefit 3, 4, 2
The European Society of Cardiology recommends avoiding complete cessation of all antiplatelet therapy if stents are present, particularly within the first year after placement, as stent thrombosis carries catastrophic consequences including MI and death 3, 7, 1

The European Society of Cardiology recommends starting 14-day triple therapy with PPI, clarithromycin, and amoxicillin for H. pylori eradication in patients on dual antiplatelet therapy 8
The American College of Cardiology suggests that this regimen is first-line therapy when clarithromycin resistance is low in the region 8
If clarithromycin resistance is high, the European Society of Cardiology recommends using 10-day sequential therapy with four drugs (amoxicillin, clarithromycin, metronidazole, and PPI) 8

The European Heart Society recommends not discontinuing aspirin or clopidogrel during H. pylori treatment unless active bleeding occurs 9, 10, 11
Complete cessation of both antiplatelet agents is an independent predictor of stent thrombosis and mortality, according to the European Heart Society 12

The European Heart Society recommends continuing PPI indefinitely while on dual antiplatelet therapy, even after completing H. pylori eradication 10
PPI co-therapy significantly reduces upper gastrointestinal bleeding risk with dual antiplatelet therapy, as stated by the European Heart Society 10

H. pylori eradication is associated with significant reduction in ulcer recurrence and rebleeding rates, according to the World Journal of Emergency Surgery 8
The European Heart Society states that interrupting both antiplatelet drugs magnifies platelet reactivity and can trigger stent thrombosis 9, 10, 11

The World Journal of Emergency Surgery recommends testing for eradication 4 weeks after completing therapy using urea breath test or stool antigen test 8
The American College of Cardiology suggests that patient must be off antibiotics and bismuth for at least 4 weeks before confirmatory testing 13

The European Heart Society recommends performing urgent interventional endoscopy (ideally within 12 hours) to identify and treat bleeding source if active bleeding occurs during treatment 9, 10, 11
The European Heart Society suggests avoiding red blood cell transfusion unless hemodynamically compromised, as transfusion increases ischemic events in patients with recent MI 9, 10

The American College of Cardiology recommends continuing clopidogrel therapy during H. pylori eradication with clarithromycin, as the cardiovascular risks of stopping antiplatelet therapy outweigh any theoretical drug interaction concerns, with a strength of evidence based on studies published in Circulation in 2010 14
The FDA advisory regarding CYP2C19 inhibitors and clopidogrel specifically addresses PPIs and does not prohibit the use of clarithromycin, as stated in the Journal of the American College of Cardiology in 2011 15

The standard H. pylori eradication regimen includes 14-day triple therapy with PPI, clarithromycin 500 mg twice daily, and amoxicillin 1000 mg twice daily, as recommended by the Gut journal in 2012 16
The American College of Cardiology suggests that PPI co-therapy significantly reduces upper gastrointestinal bleeding risk with dual antiplatelet therapy, with a strength of evidence based on a study published in the Journal of the American College of Cardiology in 2008 17
Higher-dose clarithromycin (500 mg twice daily) achieves superior eradication rates compared to 250 mg twice daily (89.5% vs 83.3%), although the specific citation for this fact is not provided, it is mentioned in the context of 16

Clarithromycin-based triple therapy remains highly effective for H. pylori eradication (86-90% cure rates), and switching to less effective regimens increases the risk of treatment failure and subsequent antibiotic resistance, as stated in the Gut journal in 2012 16
Ongoing PPI therapy provides essential protection against antiplatelet-induced GI bleeding, with a strength of evidence based on a study published in the Journal of the American College of Cardiology in 2008 17